IMV’s phase II ovarian cancer data trend positive while the stock reverses Feb. 25, 2020 By Lee Landenberger No Comments Updated results from IMV Inc.’s ongoing phase II trial of DPX-Survivac to treat advanced recurrent ovarian cancer show the company’s lead candidate was active and well-tolerated in patients. Read More